Founder and Previous CEO Matt Gevaert to Continue as Member of Board of Directors
Kiyatec, a leading biotechnology company specializing in 3D cell culture technology, is pleased to announce the promotion of Eric Perreault to the position of chief executive officer (CEO). As CEO, Eric will continue to lead Kiyatec in its mission to revolutionize cancer care by harnessing the power of functional precision medicine with its KIYA-Predict™ and 3D Predict™ platforms. He succeeds Matt Gevaert, PhD, who after more than 15 years as CEO will remain a member of Kiyatec’s Board of Directors.
“We are excited to announce Eric Perreault as the new CEO of Kiyatec,” said Gevaert, co-founder of Kiyatec. “Eric’s leadership and extensive understanding of both our technology and industry are assets that will drive Kiyatec’s continued growth. We’re confident that, under Eric’s guidance, Kiyatec will make a meaningful and enduring contribution to cancer treatment and drug discovery.”
As President of Kiyatec, Eric has been an integral part of the Kiyatec team and has played a crucial role in shaping the company’s strategic direction. With his extensive industry experience and leadership acumen, Eric’s promotion to CEO marks a significant milestone in Kiyatec’s journey. In this new position, Eric will propel Kiyatec toward commercial success by driving innovation, forging strategic partnerships, and expanding market reach.
“In my new role as CEO, my mission is to drive Kiyatec toward truly revolutionizing cancer care, especially for patients battling brain cancer, who haven’t seen any real treatment advances in decades,” said Eric. “I’m eager to continue collaborating with Matt as a member of our board and tapping into his extensive experience to propel us toward accomplishing this ambitious goal.”
As Kiyatec prepares for its next phase of growth and expansion, the company remains focused on advancing functional precision oncology with its 3D cell culture technology. With Eric Perreault as CEO, Kiyatec is well positioned to spearhead transformative change in cancer care, ultimately driving improvements in patient outcomes.
For more information about Kiyatec and its groundbreaking KIYA-Predict and 3D Predict platforms, please visit www.Kiyatec.com.
About Kiyatec:
Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. They offer clinical testing for high-grade glioma and are developing tests for ovarian, breast, non-small cell lung, and rare tumors in their CLIA-certified laboratory. Kiyatec also works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors and aims to improve patient outcomes and revolutionize the field of precision medicine. For more information, visit www.Kiyatec.com.
Media Contact:
[email protected]
